Download PDF
CC BY-NC-ND 4.0 · Journal of Gastrointestinal Infections 2022; 12(02): 117-120
DOI: 10.1055/s-0042-1757422
Brief Report

Real-World Evaluation of Response to Hepatitis B Vaccination in Cirrhosis: A Brief Report

Mayank Jain
1   Department of Gastroenterology Arihant Hospital and Research Centre, Indore, Madhya Pradesh, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints


Abstract

Information regarding seroresponse to hepatitis B virus (HBV) vaccination in India is sparse. We aimed to determine response rates to HBV vaccination in adult cirrhotic patients. We included adult patients (> 18 years) with cirrhosis after screening for hepatitis B surface antigen (HBsAg), anti-HBc, and anti-HBs. Those who were seronegative were advised vaccination. We excluded patients who were known HBsAg positive, on oral antiviral drugs, who did not complete the recommended vaccination regimen, and those who were lost to follow-up. Two months after completion of vaccination, anti-HBs titers were measured. Titers more than10 IU/L were considered as response, while less than 10 IU/L was labeled as nonresponse. The two groups were compared for baseline demographic parameters, anthropometry, model of end-stage liver disease score, and history of prior vaccination. The study cohort included 164 patients (median age: 43, range: 18–68 years, and 67% males). On follow-up at 2 months after vaccination, 103 (62.8%) patients had anti-HBs titer more than 10 IU/L. Of these, 54 (52.4%) had titers more than 100 and 49 (47.6%) had titers ranging from 10 to 99. Nonresponders were significantly older than responders (48 vs. 41 years, p = 0.01). Seroresponse to HBV vaccination in adult patients with cirrhosis was 62.8%. Older age predicted nonresponse to HBV vaccination.

Keywords

hepatitis B - vaccination - cirrhosis - serology - viral hepatitis

Ethical Statement

Written informed consent was obtained from the patients. Ethical Clearance was obtained from Ethics committee, Arihant Hospital and Research Centre, Indore, India.


Author Contributions

M.J. conceptualised, collected data, analyses, wrote the draft and approved the work.


Data Availability statement

The corresponding author will provide anonymized data on a reasonable request.




Publication History

Received: 16 May 2022

Accepted: 06 June 2022

Article published online:
22 September 2023

© 2023. Gastroinstestinal Infection Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Van Thiel DH. Vaccination of patients with liver disease: who, when, and how. Liver Transpl Surg 1998; 4 (02) 185-187
    CrossrefPubMedGoogle Scholar
  • 2 Keeffe EB, Krause DS. Hepatitis B vaccination of patients with chronic liver disease. Liver Transpl Surg 1998; 4 (05) 437-439
    CrossrefPubMedGoogle Scholar
  • 3 Trantham L, Kurosky SK, Zhang D, Johnson KD. Adherence with and completion of recommended hepatitis vaccination schedules among adults in the United States. Vaccine 2018; 36 (35) 5333-5339
    CrossrefPubMedGoogle Scholar
  • 4 Mukhtar NA, Kathpalia P, Hilton JF. et al. Provider, patient, and practice factors shape hepatitis B prevention and management by primary care providers. J Clin Gastroenterol 2017; 51 (07) 626-631
    CrossrefPubMedGoogle Scholar
  • 5 Bonazzi PR, Bacchella T, Freitas AC. et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis 2008; 12 (04) 306-309
    CrossrefPubMedGoogle Scholar
  • 6 Yang S, Tian G, Cui Y. et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep 2016; 6: 27251
    CrossrefPubMedGoogle Scholar
  • 7 Joshi SS, Davis RP, Ma MM. et al. Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD). NPJ Vaccines 2021; 6 (01) 9
    CrossrefPubMedGoogle Scholar
  • 8 Ashhab AA, Rodin H, Campos M. et al. Response to hepatitis B virus vaccination in individuals with chronic hepatitis C virus infection. PLoS One 2020; 15 (08) e0237398
    CrossrefPubMedGoogle Scholar
  • 9 Roni DA, Pathapati RM, Kumar AS, Nihal L, Sridhar K, Tumkur Rajashekar S. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol 2013; 2013: 196704
    PubMedGoogle Scholar
  • 10 Wilson JN, Nokes DJ. Do we need 3 doses of hepatitis B vaccine?. Vaccine 1999; 17 (20-21): 2667-2673
    CrossrefPubMedGoogle Scholar
  • 11 Rambusch EG, Nashan B, Tillmann HL. et al. [De novo hepatitis B infection after liver transplantation–evidence for the need of active hepatitis B vaccination of liver transplantation candidates]. Z Gastroenterol 1998; 36 (12) 1027-1035
    PubMedGoogle Scholar
  • 12 Lin CC, Yong CC, Chen CL. Active vaccination to prevent de novo hepatitis B virus infection in liver transplantation. World J Gastroenterol 2015; 21 (39) 11112-11117
    CrossrefPubMedGoogle Scholar